Loading
institutionsInstitution
Georgetown Lombardi Comprehensive Cancer Center
The only NCI comprehensive cancer centre in Washington, DC, known for breast cancer research including leadership of the CLEOPATRA pertuzumab trial.
Overview
NCI-designated since 1974, Georgetown Lombardi is Washington's only comprehensive cancer centre and since 2019 has formed a consortium with Hackensack Meridian's John Theurer Cancer Center in New Jersey. Breast cancer has been its signature: Marc Lippman and Robert Clarke built the hormone-receptor and endocrine-resistance programme, and Sandra Swain led CLEOPATRA, which established pertuzumab plus trastuzumab and docetaxel as first-line therapy for HER2-positive metastatic breast cancer. Louis Weiner's antibody immunotherapy laboratory and a cancer-prevention and population-science programme focused on the DC region round out the portfolio. Care is delivered at MedStar Georgetown University Hospital.
Location
Washington, DC, US
Type
cancer center · Georgetown University
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
NCI designation
comprehensive
OnCo score
#66 · 45 points (0 Newsweek + 15 NCI + 30 from 15 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-10-01.
Matched to Georgetown Lombardi Comprehensive Cancer Center, including child institutions. 485 works · 7,604 citations · 67% open access · 16% clinical trials · 1% reviews.
Oncology works per year
932022
1282023
1012024
952025
682026
Most works
- Stephen V. Liu55 works
- Benjamin Adam Weinberg49 works
- John Lindsay Marshall41 works
- Michael B. Atkins40 works
- Marcus Smith Noel30 works
- Joanne Xiu27 works
- Heinz‐Josef Lenz24 works
- Sandra M. Swain23 works
- Claudine J. Isaacs23 works
- Aiwu Ruth He21 works
Most cited
- Breast cancer (CLEOPATRA)
- Antibody immunotherapy
- Consortium with John Theurer Cancer Center
Michael B. Atkins
Deputy Director, Georgetown Lombardi Comprehensive Cancer Center
MelanomaKidney cancerImmunotherapy sequencing
Washington oncologist who led DREAMseq, the trial that showed people with BRAF-mutant melanoma live longer if immunotherapy is given before targeted therapy rather than after.
Sandra M. Swain
Professor of Medicine and Associate Dean for Research Development, Georgetown University Medical Center
HER2-positive breast cancerAnti-HER2 combinationsCardio-oncology
Led CLEOPATRA, which showed dual HER2 blockade with pertuzumab gives an unprecedented 16-month survival gain in metastatic disease.
Similar pages
- InstitutionApollo Hospitals (Apollo Cancer Centres)
Shares CyberKnife robotic radiosurgery, Stereotactic radiosurgery (Gamma Knife, CyberKnife, linac SRS), Proton therapy machines: cyclotrons, synchrotrons and single-room systems, Proton therapy.
- TrialA Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or M
Shares Pertuzumab, Trastuzumab, Docetaxel, HER2-positive breast cancer.
- TermDual HER2 blockade
Shares CLEOPATRA, Pertuzumab, Trastuzumab, HER2.
- TrialA Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer
Shares Pertuzumab, Trastuzumab, Docetaxel, HER2-positive breast cancer.
- TrialA Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer
Shares Pertuzumab, Trastuzumab, Docetaxel, HER2-positive breast cancer.
- TrialA Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Brea
Shares Pertuzumab, Trastuzumab, Docetaxel, HER2-positive breast cancer.
- TrialA Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive
Shares Pertuzumab, Docetaxel, HER2-positive breast cancer, Monoclonal antibodies.
- TrialA Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies
Shares Pertuzumab, Trastuzumab, Docetaxel, Monoclonal antibodies.
cancers
technologies
targets
drugs
ApprovedCytotoxic chemotherapy (taxane)
Docetaxel · Taxotere (generic)
ApprovedMonoclonal antibody (anti-HER2, dimerisation domain)
Pertuzumab · Perjeta; Phesgo (with trastuzumab, subcutaneous)
ApprovedMonoclonal antibody (anti-HER2)
Trastuzumab · Herceptin (and biosimilars, Phesgo with pertuzumab)